echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > stroke: cerebral vein thrombotic outcome due to vaccine-induced immune thrombocytopenia

    stroke: cerebral vein thrombotic outcome due to vaccine-induced immune thrombocytopenia

    • Last Update: 2022-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cerebral vein thrombosis (CVT) due to vaccine-induced immune thrombocytopenia (VITT) is a serious disease with a high


    The researchers used data from an international registry that collected patients who


    Results showed that of the 107 CVT-VITT cases, 43 (40%) died


    In summary, compared with the high mortality rate of CVT-VITT in the acute phase, the mortality rate of patients who survived the initial hospitalization was very low, no new thrombotic events occurred, and bleeding events were rare


    References:

    Outcomes of Cerebral Venous Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia After the Acute Phase.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.